Pages that link to "Q87674625"
Jump to navigation
Jump to search
The following pages link to Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial (Q87674625):
Displaying 9 items.
- Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization (Q26771165) (← links)
- Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma (Q33420546) (← links)
- Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents (Q35214924) (← links)
- Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers. (Q35757980) (← links)
- Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study (Q38845317) (← links)
- HDACs and HDAC Inhibitors in Cancer Development and Therapy (Q38947405) (← links)
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma (Q42702942) (← links)
- Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. (Q52674783) (← links)
- Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology (Q88566946) (← links)